Similar articles

• Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?

  McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM. McLaughlin T, et al. Am J Cardiol. 2005 Aug 1;96(3):399-404. doi: 10.1016/j.amjcard.2005.03.085. Am J Cardiol. 2005. PMID: 16054467
• Clustering of metabolic disorders and hyperinsulinemia in Mexico City.

  Zamora-González J, Yamamoto-Kimura L, Lerman-Garber I, Cardoso-Saldaña G, Fajardo-Gutierrez A, Posadas-Romero C. Zamora-González J, et al. Int J Obes Relat Metab Disord. 1996 Apr;20(4):311-8. Int J Obes Relat Metab Disord. 1996. PMID: 8680457
• Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.

  Glueck CJ, Glueck HI, Stroop D, Speirs J, Hamer T, Tracy T. Glueck CJ, et al. J Lab Clin Med. 1993 Oct;122(4):412-20. J Lab Clin Med. 1993. PMID: 8228555
• CME: Kardiovaskuläres Screening: Sinn, Unsinn und Bedeutung der Bestimmung von Lipoprotein(a).

  Jonas H, Annema W, von Eckardstein A, Suter PM. Jonas H, et al. Praxis (Bern 1994). 2018 Feb;107(4):215-222. doi: 10.1024/1661-8157/a002892. Praxis (Bern 1994). 2018. PMID: 29439638 Review. German. No abstract available.
• High blood cholesterol.

  National Heart, Lung and Blood Institute. National Heart, Lung and Blood Institute. Nutr Clin Care. 2003 Oct-Dec;6(3):108-14. Nutr Clin Care. 2003. PMID: 14979453 Review.